Die Bedeutung von Plazebomechanismen in der Schmerztherapie

Zusammenfassung

Die Plazeboanalgesie ist mit komplexen neurobiologischen Vorgängen assoziiert. Diese können auch die Wirksamkeit und Verträglichkeit von schmerztherapeutischen Behandlungen mit aktiven Pharmaka oder spezifischen Prozeduren erheblich beeinflussen. Die der Plazeboanalgesie zugrundeliegenden psychologischen Mechanismen Erwartung und assoziatives Lernen sollten gezielt eingesetzt werden, um schmerztherapeutische Strategien zu optimieren.

Abstract

Placebo analgesia involves complex neurobiological processes. These can also substantially modulate the efficacy and tolerability of active pharmacological and other specific treatments. Expectancy and associative learning, which represent the key psychological mechanisms underlying placebo analgesia should be systematically exploited to improve analgesic therapies.

Schlüsselwörter

Schmerztherapie - Plazebo - Kognition

Keywords

pain therapy - placebo - cognition

• Literatur

• 1 Enck P, Bingel U, Schedlowski M et al. The placebo response in medicine: minimize, maximize or personalize?. Nat Rev Drug Discov 2013; 12: 191-204
• 2 Klinger R. The potential of the analgetic placebo effect – s3-guideline recommendation on the clinical use for acute and perioperative pain management. Anasthesiol Intensivmed Notfallmed Schmerzther 2010; 45: 22-29
• 3 Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 1999; 19: 484-494
• 4 Benedetti F, Pollo A, Lopiano L et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003; 23: 4315-4323
• 5 Goebel MU, Trebst AE, Steiner J et al. Behavioral conditioning of immunosuppression is possible in humans. Faseb J 2002; 16: 1869-1873
• 6 Kaptchuk TJ, Kelley JM, Conboy LA et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003
• 7 Vase L, Riley JL, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 2002; 99: 443-452
• 8 Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-1602
• 9 Vase L, Petersen GL, Riley 3rd JL et al. Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain 2009; 145: 36-44.
• 10 Krogsboll LT, Hrobjartsson A, Gotzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC medical research methodology 2009; 9: 1
• 11 Rutherford BR, Mori S, Sneed JR et al. Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. J Psychiatr Res 2012; 46: 697-702
• 12 Haake M, Muller HH, Schade-Brittinger C et al. German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Archives of internal medicine 2007; 167: 1892-1898
• 13 Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978; 2: 654-657
• 14 Eippert F, Finsterbusch J, Bingel U et al. Direct evidence for spinal cord involvement in placebo analgesia. Science 2009; 326: 404
• 15 Eippert F, Bingel U, Schoell ED et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009; 63: 533-543
• 16 Zubieta JK, Bueller JA, Jackson LR et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 2005; 25: 7754-7762
• 17 Wager TD, Scott DJ, Zubieta JK. Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci USA 2007; 104: 11056-11061
• 18 Benedetti F, Amanzio M, Rosato R et al. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nature medicine 2011; 17: 1228-1230
• 19 Benedetti F, Carlino E, Pollo A. Hidden administration of drugs. Clin Pharmacol Ther 2011; 90: 651-661
• 20 Pollo A, Amanzio M, Arslanian A et al. Response expectancies in placebo analgesia and their clinical relevance. Pain 2001; 93: 77-84
• 21 Colloca L, Lopiano L, Lanotte M et al. Overt versus covert treatment for pain, anxiety, and Parkinson’s disease. Lancet Neurol 2004; 3: 679-684
• 22 Kirk JM, Doty P, De Wit H. Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 59: 287-293
• 23 Metrik J, Rohsenow DJ, Monti PM et al. Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana. Exp Clin Psychopharmacol 2009; 17: 217-225
• 24 Volkow ND, Wang GJ, Ma Y et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 2003; 23: 11461-11468
• 25 Bingel U, Wanigasekera V, Wiech K et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 2011; 3: 70ra14
• 26 Rief W, Nestoriuc Y, Weiss S et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009; 118: 1-8
• 27 Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med 2006; 166: 155-160
• 28 Nestoriuc Y, Orav EJ, Liang MH et al. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res 2010; 62: 791-799
• 29 Klinger R. The potential of the analgetic placebo effect – s3-guideline recommendation on the clinical use for acute and perioperative pain management. Anasthesiol Intensivmed Notfallmed Schmerzther 45: 22-29
• 30 Miller FG, Colloca L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am J Bioeth 2009; 9: 39-47
• 31 Doering BK, Rief W. Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci 2012; 33: 165-172
• 32 Goebel MU, Meykadeh N, Kou W et al. Behavioral conditioning of antihistamine effects in patients with allergic rhinitis. Psychother Psychosom 2008; 77: 227-234
• 33 Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?. J Dev Behav Pediatr 2010; 31: 369-375
• 34 Ader R, Cohen N. Behaviorally conditioned immunosuppression and murine systemic lupus erythematosus. Science 1982; 215: 1534-1536
• 35 Schedlowski M, Pacheco-Lopez G. The learned immune response: Pavlov and beyond. Brain Behav Immun 2010; 24: 176-185
• 36 Hall KT, Lembo AJ, Kirsch I et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PloS one 2012; 7: e48135
• 37 Stein N, Sprenger C, Scholz J et al. White matter integrity of the descending pain modulatory system is associated with interindividual differences in placebo analgesia. Pain 2012; 153: 2210-2217
• 38 Kong J, Jensen K, Loiotile R et al. Functional connectivity of frontoparietal network predicts cognitive modulation of pain. Pain 2013; 154: 459-467
• 39 Hashmi JA, Baria AT, Baliki MN et al. Brain networks predicting placebo analgesia in a clinical trial for chronic back pain. Pain 2012; 153: 2393-2402
• 40 Benedetti F, Arduino C, Costa S et al. Loss of expectation-related mechanisms in Alzheimer’s disease makes analgesic therapies less effective. Pain 2006; 121: 133-144
• 41 Rief W, Bingel U, Schedlowski M et al. Mechanisms Involved in Placebo and Nocebo Responses and Implications for Drug Trials. Clin Pharmacol Ther 2011;
• 42 Laferton JA, Shedden Mora M, Auer CJ et al. Enhancing the efficacy of heart surgery by optimizing patients’ preoperative expectations: study protocol of a randomized controlled trial. Am Heart J 2013; 165: 1-7